J.M. Eddins Jr./The Washington Times BITTER PILL: John Castellani, president and CEO of PhRMA, cautions against cutting from 12 years to seven the length of a patent on a company’s new drug.
Wednesday, September 28, 2011
PhRMA shroud waving 101 - Curtailing patents will cripple R&D on pharmaceuticals, industry warns - Washington Times
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment